HT
ENTA icon

Headlands Technologies’s Enanta Pharmaceuticals ENTA Stock Holding History

Headlands Technologies’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$286K Buy
22,618
+22
+0.1% +$295 0.03% 511
2025
Q4 		$356K Buy
+22,596
New +$287K 0.03% 479
2025
Q2 		– Sell
-361
Closed -$1.99K – 1277
2025
Q1 		$1.99K Buy
+361
New +$2.23K ﹤0.01% 1044
2024
Q4 		– Sell
-1,322
Closed -$13.7K – 1292
2024
Q3 		$13.7K Buy
+1,322
New +$17.3K ﹤0.01% 998
2024
Q2 		– Sell
-1,052
Closed -$18.4K – 1261
2024
Q1 		$18.4K Buy
+1,052
New +$13.9K ﹤0.01% 928

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Headlands Technologies's ENTA Position: Q1 2026 in Review

Headlands Technologies increased its Enanta Pharmaceuticals (ENTA) stake by 0.1% in Q1 2026, buying an estimated $295 and bringing the position to 22,618 shares worth $286K. The position accounts for 0.03% of the portfolio, ranked #511.

Headlands Technologies first reported a position in ENTA in Q1 2024 and has held it in 5 quarters since. The position peaked at $356K in Q4 2025. 133 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Headlands Technologies held 22,618 shares of Enanta Pharmaceuticals worth $286K as of Q1 2026.
  • Headlands Technologies bought 22 Enanta Pharmaceuticals shares in Q1 2026, an estimated $295.
  • Enanta Pharmaceuticals made up 0.03% of Headlands Technologies's portfolio in Q1 2026, its #511 holding.
  • Headlands Technologies first reported a position in Enanta Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
  • Headlands Technologies's Enanta Pharmaceuticals position peaked at $356K in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.